FR2970967B1 - Derives de type azaindazole ou diazaindazole comme medicament - Google Patents

Derives de type azaindazole ou diazaindazole comme medicament

Info

Publication number
FR2970967B1
FR2970967B1 FR1150651A FR1150651A FR2970967B1 FR 2970967 B1 FR2970967 B1 FR 2970967B1 FR 1150651 A FR1150651 A FR 1150651A FR 1150651 A FR1150651 A FR 1150651A FR 2970967 B1 FR2970967 B1 FR 2970967B1
Authority
FR
France
Prior art keywords
diazaindazole
azaindazole
derivatives
medicinal product
medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1150651A
Other languages
English (en)
French (fr)
Other versions
FR2970967A1 (fr
Inventor
El Bachir Kaloun
Karim Bedjeguelal
Remi Rabot
Anna Kruczynski
Philippe Schmitt
Michel Perez
Nicolas Rahier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR1150651A priority Critical patent/FR2970967B1/fr
Priority to TW101102531A priority patent/TWI546303B/zh
Priority to ARP120100272A priority patent/AR084935A1/es
Priority to KR1020137022330A priority patent/KR101923751B1/ko
Priority to ES12701884.4T priority patent/ES2661695T3/es
Priority to PCT/EP2012/051283 priority patent/WO2012101239A1/en
Priority to HUE12701884A priority patent/HUE037153T2/hu
Priority to MX2013008673A priority patent/MX356411B/es
Priority to US13/823,658 priority patent/US20130172360A1/en
Priority to DK12701884.4T priority patent/DK2668184T3/en
Priority to LTEP12701884.4T priority patent/LT2668184T/lt
Priority to MA36177A priority patent/MA34903B1/fr
Priority to KR1020187031264A priority patent/KR20180122028A/ko
Priority to EP12701884.4A priority patent/EP2668184B1/en
Priority to RU2013138624/04A priority patent/RU2600976C2/ru
Priority to AU2012210467A priority patent/AU2012210467B2/en
Priority to PL12701884T priority patent/PL2668184T3/pl
Priority to UAA201310425A priority patent/UA109698C2/ru
Priority to CA2823824A priority patent/CA2823824C/en
Priority to NZ614432A priority patent/NZ614432B2/en
Priority to BR112013018852-9A priority patent/BR112013018852B1/pt
Priority to SI201231273T priority patent/SI2668184T1/en
Priority to PT127018844T priority patent/PT2668184T/pt
Priority to RS20180418A priority patent/RS57101B1/sr
Priority to CN201280006671.8A priority patent/CN103339129B/zh
Priority to JP2013550886A priority patent/JP5931926B2/ja
Priority to MYPI2013002799A priority patent/MY180666A/en
Priority to TR2018/02944T priority patent/TR201802944T4/tr
Priority to HRP20180524TT priority patent/HRP20180524T1/hr
Priority to HK13114261.8A priority patent/HK1186737B/xx
Publication of FR2970967A1 publication Critical patent/FR2970967A1/fr
Priority to US13/686,334 priority patent/US8883821B2/en
Application granted granted Critical
Publication of FR2970967B1 publication Critical patent/FR2970967B1/fr
Priority to TNP2013000293A priority patent/TN2013000293A1/fr
Priority to IL227496A priority patent/IL227496B/en
Priority to IL257748A priority patent/IL257748B/en
Priority to CY20181100338T priority patent/CY1120088T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR1150651A 2011-01-27 2011-01-27 Derives de type azaindazole ou diazaindazole comme medicament Active FR2970967B1 (fr)

Priority Applications (35)

Application Number Priority Date Filing Date Title
FR1150651A FR2970967B1 (fr) 2011-01-27 2011-01-27 Derives de type azaindazole ou diazaindazole comme medicament
TW101102531A TWI546303B (zh) 2011-01-27 2012-01-20 氮雜吲唑（ａｚａｉｎｄａｚｏｌｅ）或二氮雜吲唑（ｄｉａｚａｉｎｄａｚｏｌｅ）類型之衍生物供作藥物之用途
BR112013018852-9A BR112013018852B1 (pt) 2011-01-27 2012-01-27 Derivados do tipo azaindazol ou diazaindazol, seus usos na preparação de fármacos, métodos de preparação dos mesmos, e composições farmacêuticas compreendendo os referidos compostos
ES12701884.4T ES2661695T3 (es) 2011-01-27 2012-01-27 Derivados de tipo azaindazol o diazaindazol como medicamento
PCT/EP2012/051283 WO2012101239A1 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament
HUE12701884A HUE037153T2 (hu) 2011-01-27 2012-01-27 Azaindazol vagy diazaindazol típusú származékok mint gyógyszerek
MX2013008673A MX356411B (es) 2011-01-27 2012-01-27 Derivados del tipo del azaindazol o diazaindazol como medicamento.
US13/823,658 US20130172360A1 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament
DK12701884.4T DK2668184T3 (en) 2011-01-27 2012-01-27 DERIVATIVES OF AZAINDAZOL OR DIAZAINDAZOL TYPE AS MEDICATION
LTEP12701884.4T LT2668184T (lt) 2011-01-27 2012-01-27 Azaindazolo arba diazaindazolo tipo dariniai kaip vaistai
PT127018844T PT2668184T (pt) 2011-01-27 2012-01-27 Derivados do tipo azaindazole ou diazaindazole utilizados como medicamentos
KR1020187031264A KR20180122028A (ko) 2011-01-27 2012-01-27 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체
EP12701884.4A EP2668184B1 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament
RU2013138624/04A RU2600976C2 (ru) 2011-01-27 2012-01-27 Производные азаиндазола или диазаиндазола в качестве медикамента
AU2012210467A AU2012210467B2 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament
PL12701884T PL2668184T3 (pl) 2011-01-27 2012-01-27 Pochodne typu azaindazolu lub diazaindazolu jako lek
UAA201310425A UA109698C2 (xx) 2011-01-27 2012-01-27 Похідні азаіндазолу або діазаіндазолу як медикамент
CA2823824A CA2823824C (en) 2011-01-27 2012-01-27 Derivatives of azaindazoles and diazaindazoles and their use as medicaments
ARP120100272A AR084935A1 (es) 2011-01-27 2012-01-27 Derivados de tipo azaindazol o diazaindazol como medicamentos
SI201231273T SI2668184T1 (en) 2011-01-27 2012-01-27 PRODUCTS OF AZAINDAZOL OR DIAZAINDAZOL AS A MEDICINAL PRODUCT
KR1020137022330A KR101923751B1 (ko) 2011-01-27 2012-01-27 의약으로서의 아자인다졸 또는 디아자인다졸 유형의 유도체
MA36177A MA34903B1 (fr) 2011-01-27 2012-01-27 Derives de type azaindazole ou diazaindazole utilises comme medicaments
RS20180418A RS57101B1 (sr) 2011-01-27 2012-01-27 Derivati tipa azaindazola ili diazaindazola kao lek
CN201280006671.8A CN103339129B (zh) 2011-01-27 2012-01-27 作为药物的氮杂吲唑或二氮杂吲唑类衍生物
JP2013550886A JP5931926B2 (ja) 2011-01-27 2012-01-27 医薬としてのアザインダゾールまたはジアザインダゾール型の誘導体
MYPI2013002799A MY180666A (en) 2011-01-27 2012-01-27 Substituted pyrazolo [3,4-b] pyridines as medicaments
TR2018/02944T TR201802944T4 (tr) 2011-01-27 2012-01-27 İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
HRP20180524TT HRP20180524T1 (hr) 2011-01-27 2012-01-27 Derivati tipa azaindazola ili diazaindazola kao lijek
HK13114261.8A HK1186737B (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament
NZ614432A NZ614432B2 (en) 2011-01-27 2012-01-27 Derivatives of azaindazole or diazaindazole type as medicament
US13/686,334 US8883821B2 (en) 2011-01-27 2012-11-27 Substituted pyrazolo[3,4-b]pyridines as medicaments
TNP2013000293A TN2013000293A1 (en) 2011-01-27 2013-07-11 Derivatives of azaindazole or diazaindazole type as medicament
IL227496A IL227496B (en) 2011-01-27 2013-07-16 Pyrazolo[4,3–b]pyridines are converted as drugs
IL257748A IL257748B (en) 2011-01-27 2018-02-26 Derivatives of pyrazole [4,3-b]pyridine, pyrazolo[4,3-b]pyridine and pyrazolo[4,3-b]pyrazine for use in the treatment of cancer, inflammatory diseases and neurodegenerative diseases,
CY20181100338T CY1120088T1 (el) 2011-01-27 2018-03-26 Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου ως φαρμακo

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1150651A FR2970967B1 (fr) 2011-01-27 2011-01-27 Derives de type azaindazole ou diazaindazole comme medicament

Publications (2)

Publication Number Publication Date
FR2970967A1 FR2970967A1 (fr) 2012-08-03
FR2970967B1 true FR2970967B1 (fr) 2013-02-15

Family

ID=44318089

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1150651A Active FR2970967B1 (fr) 2011-01-27 2011-01-27 Derives de type azaindazole ou diazaindazole comme medicament

Country Status (30)

Country Link
US (2) US20130172360A1 (enExample)
EP (1) EP2668184B1 (enExample)
JP (1) JP5931926B2 (enExample)
KR (2) KR20180122028A (enExample)
CN (1) CN103339129B (enExample)
AR (1) AR084935A1 (enExample)
AU (1) AU2012210467B2 (enExample)
BR (1) BR112013018852B1 (enExample)
CA (1) CA2823824C (enExample)
CY (1) CY1120088T1 (enExample)
DK (1) DK2668184T3 (enExample)
ES (1) ES2661695T3 (enExample)
FR (1) FR2970967B1 (enExample)
HR (1) HRP20180524T1 (enExample)
HU (1) HUE037153T2 (enExample)
IL (2) IL227496B (enExample)
LT (1) LT2668184T (enExample)
MA (1) MA34903B1 (enExample)
MX (1) MX356411B (enExample)
MY (1) MY180666A (enExample)
PL (1) PL2668184T3 (enExample)
PT (1) PT2668184T (enExample)
RS (1) RS57101B1 (enExample)
RU (1) RU2600976C2 (enExample)
SI (1) SI2668184T1 (enExample)
TN (1) TN2013000293A1 (enExample)
TR (1) TR201802944T4 (enExample)
TW (1) TWI546303B (enExample)
UA (1) UA109698C2 (enExample)
WO (1) WO2012101239A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
JP6302846B2 (ja) 2012-02-22 2018-03-28 サンフォード−バーンハム メディカル リサーチ インスティテュート Ｔｎａｐ阻害剤としてのスルホンアミド化合物およびその使用
EP3176170B1 (en) 2012-06-13 2018-11-14 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
EP2689778A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
EP2689779A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016096709A1 (en) 2014-12-16 2016-06-23 Eudendron S.R.L. Heterocyclic derivatives modulating activity of certain protein kinases
MX373169B (es) 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
US10211205B2 (en) * 2016-04-27 2019-02-19 International Business Machines Corporation Field effect transistor structure for reducing contact resistance
CN108570052A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元杂环并吡嗪化合物、制备方法、中间体、组合和应用
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN112313232B (zh) * 2018-05-02 2024-03-08 Jw中外制药公司 新型杂环衍生物
CR20240498A (es) 2018-05-04 2025-01-08 Incyte Corp FORMAS SÓLIDAS DE UN INHIBIDOR DE FGFR Y PROCESOS PARA PREPARARLAS (Divisional EXP. 2020-0590)
BR112020022373A2 (pt) 2018-05-04 2021-02-02 Incyte Corporation sais de um inibidor de fgfr
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
PE20221504A1 (es) 2019-12-04 2022-09-30 Incyte Corp Derivados de un inhibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
UY39005A (es) * 2019-12-31 2021-07-30 Ifm Due Inc Compuestos y composiciones para tratar afecciones asociadas con la actividad de sting
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021197467A1 (zh) * 2020-04-02 2021-10-07 上海华汇拓医药科技有限公司 多靶点的抗肿瘤化合物及其制备方法和应用
JP2024500636A (ja) * 2020-11-20 2024-01-10 ２６９２３７２ オンタリオ，インク． ベンゼンスルホンアミド誘導体およびその使用
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
EP4352059A1 (en) 2021-06-09 2024-04-17 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2024522188A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199902301T2 (xx) * 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
CZ20024176A3 (cs) 2000-06-22 2004-01-14 Pfizer Inc. Způsob výroby pyrazolopyrimidinonů
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
AU2006283940A1 (en) * 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 MAP kinase inhibitors and methods for using the same
JP2009543867A (ja) 2006-07-17 2009-12-10 メルク エンド カムパニー インコーポレーテッド 抗ｈｉｖ剤としての１−ヒドロキシナフチリジン化合物
US8114865B2 (en) 2006-12-20 2012-02-14 Nerviano Medical Sciences S.R.L. Indazole derivatives as kinase inhibitors for the treatment of cancer
KR101636312B1 (ko) 2007-07-20 2016-07-05 네르비아노 메디칼 사이언시스 에스.알.엘. 키나제 억제제로서 활성인 치환된 인다졸 유도체
WO2010069966A1 (en) 2008-12-18 2010-06-24 Nerviano Medical Sciences S.R.L. Substituted indazole derivatives active as kinase inhibitors
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament

Also Published As

Publication number Publication date
IL227496A0 (en) 2013-09-30
IL257748A (en) 2018-04-30
LT2668184T (lt) 2018-04-10
HRP20180524T1 (hr) 2018-05-04
CN103339129B (zh) 2015-07-29
JP5931926B2 (ja) 2016-06-08
TWI546303B (zh) 2016-08-21
AU2012210467B2 (en) 2016-07-07
JP2014503574A (ja) 2014-02-13
TR201802944T4 (tr) 2018-03-21
CA2823824C (en) 2018-12-11
US20130085144A1 (en) 2013-04-04
MA34903B1 (fr) 2014-02-01
PL2668184T3 (pl) 2018-06-29
WO2012101239A1 (en) 2012-08-02
RU2013138624A (ru) 2015-03-10
IL227496B (en) 2019-02-28
MY180666A (en) 2020-12-04
RS57101B1 (sr) 2018-06-29
BR112013018852B1 (pt) 2021-12-21
KR20180122028A (ko) 2018-11-09
KR20140014147A (ko) 2014-02-05
NZ614432A (en) 2015-03-27
IL257748B (en) 2020-06-30
ES2661695T3 (es) 2018-04-03
HK1186737A1 (en) 2014-03-21
TW201247664A (en) 2012-12-01
MX356411B (es) 2018-05-24
UA109698C2 (xx) 2015-09-25
AU2012210467A1 (en) 2013-09-12
AR084935A1 (es) 2013-07-10
MX2013008673A (es) 2013-12-02
EP2668184B1 (en) 2018-01-10
KR101923751B1 (ko) 2018-11-29
DK2668184T3 (en) 2018-03-12
US20130172360A1 (en) 2013-07-04
CY1120088T1 (el) 2018-12-12
US8883821B2 (en) 2014-11-11
PT2668184T (pt) 2018-03-13
HUE037153T2 (hu) 2018-08-28
TN2013000293A1 (en) 2015-01-20
CA2823824A1 (en) 2012-08-02
RU2600976C2 (ru) 2016-10-27
FR2970967A1 (fr) 2012-08-03
SI2668184T1 (en) 2018-06-29
EP2668184A1 (en) 2013-12-04
CN103339129A (zh) 2013-10-02
BR112013018852A2 (pt) 2017-08-15

Similar Documents

Publication Publication Date Title
FR2970967B1 (fr) Derives de type azaindazole ou diazaindazole comme medicament
ZA201406968B (en) Soft chewable pharmaceutical product
LT3470063T (lt) Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
DK3501558T3 (da) Flydbare vævsprodukter
EP2858630A4 (en) Nanotherapeutics for drug targeting
BR112014012778A2 (pt) embalagem de cateter
EP2568979A4 (en) RATIOMETRIC COMBINATORY MEDICINE ADMINISTRATION
EP2695621A4 (en) PHARMACEUTICAL PREPARATION
CL2014003283A1 (es) Formulación farmacéutica.
BR112014015885A2 (pt) preparação farmacêutica
IL231622B (en) Pharmaceutical composition for treatment of cachexia
EP2720707A4 (en) INFLAMMATORY PHARMACEUTICAL PRODUCTS
EP2668186A4 (en) PHARMACEUTICAL COMPOSITION WITH PYRIDIDE DERIVATIVES
EP2671578A4 (en) PROPHYLACTIC OR THERAPEUTIC MEDICINE FOR PERIPHERAL NEUROPATHY CAUSED BY AN ANTICANCER AGENT
DK3473255T3 (da) Farmaceutisk formulering omfattende ciclesonid
ZA201405925B (en) Pharmaceutical formulation having improved stability
BR302012006318S1 (pt) Configuração aplicada em vaporizador de produtos fluidos
GB201206384D0 (en) Antibacterial drug derivatives
EP2668185A4 (en) PHARMACEUTICAL COMPOSITION WITH PYRIDIDE DERIVATIVES
HUE049344T2 (hu) Gyermekgyógyászati készítmény
BR302012006320S1 (pt) Configuração aplicada em vaporizador de produtos fluidos
GB201222679D0 (en) Pharmaceutical combination products
AU2012265231A1 (en) Nasal pharmaceutical formulation
IT1399867B1 (it) Inserto illustrativo per medicinali.
GB201206383D0 (en) Antibacterial drug derivatives

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15